The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.

We have identified specific iron (Fe) chelators of the pyridoxal isonicotinoyl hydrazone (PIH) class that are far more effective ligands than desferrioxamine (DFO; Richardson et al, Blood 86:4295, 1995; Richardson and Milnes, Blood 89:3025, 1997). In the present study, we have compared the effect of DFO and one of the most active chelators (2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone; 311) on molecular targets involved in proliferation. This was performed to further understand the mechanisms involved in the antitumor activity of Fe chelators. Ligand 311 was far more active than DFO at increasing Fe release from SK-N-MC neuroepithelioma and BE-2 neuroblastoma cells and preventing Fe uptake from transferrin. Like DFO, 311 increased the RNA-binding activity of the iron-regulatory proteins (IRPs). However, despite the far greater Fe chelation efficacy of 311 compared with DFO, a similar increase in IRP-RNA binding activity occurred after 2 to 4 hours of incubation with either chelator, and the binding activity was not inhibited by cycloheximide. These results suggest that, irrespective of the Fe chelation efficacy of a ligand, an increase IRP-RNA binding activity occurred via a time-dependent step that did not require protein synthesis. Further studies examined the effect of 311 and DFO on the expression of p53-transactivated genes that are crucial for cell cycle control and DNA repair, namely WAF1, GADD45, and mdm-2. Incubation of 3 different cell lines with DFO or 311 caused a pronounced concentration- and time-dependent increase in the expression of WAF1 and GADD45 mRNA, but not mdm-2 mRNA. In accordance with the distinct differences in Fe chelation efficacy and antiproliferative activity of DFO and 311, much higher concentrations of DFO (150 micromol/L) than 311 (2.5 to 5 micromol/L) were required to markedly increase GADD45 and WAF1 mRNA levels. The increase in GADD45 and WAF1 mRNA expression was seen only after 20 hours of incubation with the chelators and was reversible after removal of the ligands. In contrast to the chelators, the Fe(III) complexes of DFO and 311 had no effect on increasing GADD45 and WAF1 mRNA levels, suggesting that Fe chelation was required. Finally, the increase in GADD45 and WAF1 mRNAs appeared to occur by a p53-independent pathway in SK-N-MC and K562 cells, because these cell lines lack functional p53. Our results suggest that GADD45 and WAF1 may play important roles in the cell cycle arrest observed after exposure to these chelators.

[1]  P. Ponka,et al.  A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. , 1979, Biochimica et biophysica acta.

[2]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[3]  M. Mahmoudi,et al.  Comparison of two different hybridization systems in northern transfer analysis. , 1989, BioTechniques.

[4]  D. Richardson Potential of iron chelators as effective antiproliferative agents. , 1997, Canadian journal of physiology and pharmacology.

[5]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[6]  S. Bi,et al.  p53 in chronic myeloid leukemia cell lines. , 1992, Leukemia.

[7]  A. Davidoff,et al.  Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. , 1992, Oncogene.

[8]  D. Becton,et al.  Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. , 1989, Cancer research.

[9]  G. Kontoghiorghes,et al.  Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. , 1989, Cancer Research.

[10]  H. Munro,et al.  Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5' untranslated region of ferritin heavy- and light-subunit mRNAs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Richardson,et al.  The uptake of iron and transferrin by the human malignant melanoma cell. , 1990, Biochimica et biophysica acta.

[12]  Barbara Neupert,et al.  A specific mRNA binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor mRNA , 1989, Cell.

[13]  R. Hider,et al.  Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. , 1992, Cancer research.

[14]  L. V. van Grunsven,et al.  The CDK inhibitor p21WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells. , 1996, Oncogene.

[15]  R. Klausner,et al.  Cellular regulation of the iron-responsive element binding protein: disassembly of the cubane iron-sulfur cluster results in high-affinity RNA binding. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Ponka,et al.  Mobilization of iron from reticulocytes , 1979, FEBS letters.

[17]  D. Richardson Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities , 1997, Antimicrobial agents and chemotherapy.

[18]  D. Richardson,et al.  Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. , 1998, The Journal of laboratory and clinical medicine.

[19]  M. Brechbiel,et al.  Tumor cell cytotoxicity of a novel metal chelator. , 1998, Blood.

[20]  C. Hershko,et al.  Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. , 1981, The Journal of laboratory and clinical medicine.

[21]  G. Stark,et al.  p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Hefter,et al.  Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part II. Formation constants with iron(III) and iron(II) , 1990 .

[23]  D. Richardson,et al.  The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. , 1997, Biochimica et biophysica acta.

[24]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[25]  M. Freedman,et al.  Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. , 1984, Blood.

[26]  L. Pickart,et al.  Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone , 1982 .

[27]  D. Givol,et al.  Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.

[28]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. , 1997, Blood.

[29]  G. Mann,et al.  Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. , 1993, The Journal of biological chemistry.

[30]  W. El-Deiry,et al.  Regulation of p21WAF1/CIP1 expression by p53-independent pathways. , 1996, Oncogene.

[31]  J Lucas,et al.  Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. , 1993, Cancer research.

[32]  D. Lane,et al.  What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .

[33]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[34]  K. Ganeshaguru,et al.  Effect of Iron Deficiency and Desferrioxamine on DNA Synthesis in Human Cells , 1976, British journal of haematology.

[35]  M. Hentze,et al.  Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[37]  R. G. Hughes,et al.  Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators. , 1984, Biochemical and biophysical research communications.

[38]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[39]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.

[40]  A. Gräslund,et al.  Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. , 1983, Biochemical and biophysical research communications.

[41]  A. Donfrancesco,et al.  Deferoxamine, Cyclophosphamide, Etoposide, Carboplatin, and Thiotepa (D‐CECaT): A New Cytoreductive Chelation‐Chemotherapy Regimen in Patients with Advanced Neuroblastoma , 1992, American journal of clinical oncology.

[42]  G. Wahl,et al.  A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. , 1996, Genes & development.

[43]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[44]  D. Becton,et al.  Deferoxamine inhibition of human neuroblastoma viability and proliferation. , 1988, Cancer research.

[45]  N. Gray,et al.  Modulation of the RNA-binding activity of a regulatory protein by iron in vitro: switching between enzymatic and genetic function? , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Donfrancesco,et al.  Effects of a single course of deferoxamine in neuroblastoma patients. , 1990, Cancer research.

[47]  C. Chitambar,et al.  Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis. , 1995, Cancer research.

[48]  Z. Estrov,et al.  In vitro and in vivo effects of deferoxamine in neonatal acute leukemia , 1987 .

[49]  P. Reichard,et al.  Reduction of ribonucleotides. , 1979, Annual review of biochemistry.

[50]  J. Blatt,et al.  Mechanism of antineuroblastoma activity of deferoxamine in vitro. , 1988, The Journal of laboratory and clinical medicine.

[51]  U. Moll,et al.  Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage , 1996, Molecular and cellular biology.

[52]  W. El-Deiry,et al.  AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression , 1997, Nature Genetics.

[53]  X. H. Wang,et al.  In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. , 1987, Blood.

[54]  U. Gullberg,et al.  Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[55]  R. Klausner,et al.  cis-trans models for post-transcriptional gene regulation. , 1989, Science.

[56]  J. Domenico,et al.  Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation. , 1993, Blood.

[57]  M. Hentze,et al.  Nitric oxide and oxidative stress (H2O2) control mammalian iron metabolism by different pathways , 1996, Molecular and cellular biology.